



THE DESK OF THE PRESIDENT



Dr. R. Varadarajan
Founder President of
NES-SVB

INSIGHTS

T Regulatory Cells: A once-dismissed idea revealed T regulatory cells as key guardians preventing a utoimmune disease.

Nimesulide Ban: India bans >100 mg immediate-release Nimesulide to reduce liver toxicity risks.

Steriwave Innovation: Steriwave antimicrobial therapy offers a fast, non-antibiotic approach to prevent surgical infections.

Generic Semaglutide Launch: Dr. Reddy's Laboratories introduces affordable generic Semaglutide for diabetes care in India.

CONTRIBUTERS

Students of B.pharm

My Dear Students,

Our commitment at Saraswathi Vidya Bhavan's College of Pharmacy is to provide a safe and intellectually challenging environment that will empower students to become innovative thinkers, creative problem solvers and Inspired learners to thrive in the twenty-first century. Our college upholds high standards and benchmarks for each student in academic performance, extracurricular activities and ensuring a strong foundation for their holistic development. It is with pride that we hold these high standard and ask each of our students to commit to maintaining the extraordinary record of achievement and contribution that has been the legacy of SVBCP students.

We have walked an increiftible journey of 32 years in the midst of this journey we have earned various honour's, awards and accolades. These achievements should empower you all with a stronger resolve to work yet harder until college reckoned as one of the best.

I'm very happy that the students have successfully published the new edition of "SVBCP TIMES"

Dear students, your enthusiasm published and willingness maka me really very proud. Wish you a meaningful, enjoyable and memorable year 2025-26.

Dr. R. Varadarajan Founder President of NES-SVB



VISION

To stand distinguished as a center of Excellence that fosters talent, research aptitude, entrepreneurship, human values and holistic development of competent healthcare professional to fulfill the requirement of the industry.


MISSION

- To provide state-of-the-art infrastructure and a teaching-learning environment that is conducive for holistic development.
- To instill the values of discipline, integrity, humanity and professionalism required for the healthcare sector.
- To nurture young professional leaders to work towards novel research ideas, innovation and entrepreneurial thinking for benefit of the community, at large.



A New Hope for Autoimmunity: Scientists Discover the Body's Own Cure

Back in the 1970s, scientists believed there were special “suppressor T cells” that kept the immune system in check, but the idea lacked solid proof and slowly faded away. For years, the concept remained a scientific mystery—until one curious researcher decided to revisit it. In 1995, Japanese immunologist Shimon Sakaguchi conducted a simple yet groundbreaking experiment. He removed a small group of T cells from mice—specifically CD4⁺CD25⁺ cells—and observed something unexpected. The mice began developing severe autoimmune diseases. Their immune systems started attacking their own organs, revealing that something crucial was missing. Sakaguchi then reintroduced those same cells back into the mice. Remarkably, the autoimmune symptoms were prevented. This was the turning point.



These cells were not just ordinary T cells—they were regulators of the immune system. In the early 2000s, another major discovery followed. Scientists identified a gene called FOXP3, which acted like a master switch controlling these regulatory cells. When this gene was defective, patients developed severe autoimmune conditions, confirming the importance of these cells in humans. What began as a dismissed idea had now become one of the most important discoveries in immunology. T regulatory cells were finally recognized as the body's natural defense against self-destruction. Today, this discovery continues to inspire new therapies and research. It stands as a powerful reminder that even forgotten scientific ideas can lead to revolutionary breakthroughs.

Public Health Alert: Nimesulide >100 mg Immediate Release Formulations prohibited in India



India's Ministry of Health & Family Welfare (MoHFW) has issued a significant public health directive banning all immediate-release formulations of Nimesulide exceeding 100 mg, with immediate effect. Nimesulide, a widely used non-steroidal anti-inflammatory drug (NSAID), has long been prescribed for pain and inflammation; however, growing evidence from clinical studies and pharmacovigilance data has raised concerns about its safety at higher doses.

Reports have consistently linked doses above 100 mg—particularly in immediate-release forms—to an increased risk of hepatotoxicity, along with gastrointestinal and systemic adverse effects, especially when used over extended periods.

This regulatory action reflects both national and global efforts to minimize drug-induced liver injury and improve patient safety. Data from India's Pharmacovigilance Program (PvPI) indicate that a substantial proportion of adverse drug reactions associated with Nimesulide were tied to higher-dose formulations. In line with recommendations from organizations such as the WHO and ICMR, limiting NSAID dosage is considered a critical step in reducing preventable harm.

The ban has immediate implications for the pharmaceutical supply chain, requiring manufacturers, distributors, and pharmacies to cease production and withdraw non-compliant products. Healthcare providers are advised to reassess current prescriptions and transition patients to safer alternatives or approved doses of 100 mg or below. Patients currently taking higher doses are strongly encouraged to consult their healthcare providers before making any changes.

Overall, the move underscores the importance of regulatory vigilance and responsible prescribing practices. It also highlights the shared responsibility of healthcare professionals and the pharmaceutical industry in ensuring that patient safety remains at the forefront of therapeutic decision-making.

Steriwave Phase 3 Trial Near Completion: A Breakthrough in Infection Prevention

The fight against antimicrobial resistance (AMR) is driving innovation beyond traditional antibiotics, with promising technologies like Steriwave developed by Ondine Biomedical gaining attention. Steriwave is a non-invasive, light-activated antimicrobial therapy applied inside the nasal cavity before surgery, where a photosensitizing agent binds to microbes and, upon light activation, produces reactive oxygen species (ROS) that rapidly destroy bacteria, viruses, and fungi within minutes.



This approach is particularly important in preventing surgical site infections (SSIs), which often originate from bacteria present in a patient's own nasal passages and can lead to increased hospital stays, complications, and costs. Unlike traditional methods that rely on antibiotics and contribute to resistance, Steriwave offers a fast, broad-spectrum, non-antibiotic alternative administered by healthcare professionals to ensure compliance. Its effectiveness is currently being evaluated in the Phase 3 LANTERN trial, a large multi-center study involving over 5,000 patients across North America, which has now reached 93% enrolment, indicating that completion is near and top-line results are expected in 2026. If successful, Steriwave could significantly reduce reliance on antibiotics, improve surgical outcomes, and potentially become a standard pre-surgical procedure worldwide, with future applications in ICU and respiratory infection control, marking a major step toward safer and more advanced infection prevention in modern healthcare.

Dr Reddy's to launch generic semaglutide in India



Dr. Reddy's Laboratories has strengthened its position in India's diabetes and obesity therapy space by launching Obeda, the country's first DCGI-approved generic semaglutide injection immediately after the patent expiry of the innovator drug, making it a "day-one" generic entry and giving the company a first-mover advantage in a highly competitive GLP-1 market. The once-weekly injectable is available in pre-filled pen devices (2 mg and 4 mg strengths) designed for ease of use and improved patient adherence, with each pen covering about four doses and priced at around ₹4,200 per month, significantly lower than earlier branded alternatives.

The product is supported by a Phase III head-to-head clinical study involving over 300 patients, which demonstrated non-inferior efficacy and a comparable safety profile to the innovator semaglutide, including similar reductions in HbA1c, fasting glucose, and post-prandial glucose levels. Alongside the drug launch, the company has also introduced a patient support program (SemaKare) that includes digital guidance, injection training, and adherence monitoring, reflecting a broader strategy to build an integrated diabetes care ecosystem rather than just offering a standalone product.

This launch comes at a critical time, as India faces a massive and growing burden of diabetes with over 100 million affected individuals and a large pre-diabetic population, driving demand for more effective and scalable therapies. The expiration of semaglutide's patent has triggered a rapid influx of generic versions from multiple domestic pharmaceutical companies, leading to aggressive price competition and expected reductions of 50–90% compared to originator drugs, which is likely to significantly expand access but also intensify market competition and regulatory scrutiny. Overall, Dr. Reddy's entry not only marks a major milestone in peptide-based drug development and domestic manufacturing capabilities but also signals the beginning of a large-scale transformation in India's GLP-1 therapy segment, where affordability, accessibility, and competitive differentiation will play a key role in shaping future market dynamics.



ACHIEVEMENTS



3 UG projects were selected for Final Round in 20th AVISHKAR Research Convention



Participation in Rx by IPA-MSB-SF resulted in securing First and Second prizes in most events.



Won Best Presenter Award at PosterVerse 2k26 at Indala college of pharmacy



OUR SUPPORT PILLARS



DR.R.VARADARAJAN
Founder President, NES-SVB



DR.BALASUBRAMANIAN V.
Director, NES-SVB



DR.SANDHYA PARAMESWARAN
Principal, SVBCP

We the students of SVBCP are greatful to the Founder President, Director NES-SVB and the Principal of our college for giving us this opportunity to create newsletter and propagate the innovative ideas that develop in the field of Pharmacy.

Co-ordinators

CLASS REPRESENTATIVES

Ms.Sakshi Naik

Ayushya Upadhyay LY
Jay S Pansare LY
Sanjyot Varvatkar LY
Pooja Swami LY

Roshni Poojary TY
Vansh Chopra TY
Kajal Gupta TY
Tanmay Rane TY

Ms.Manjusha Sanap

Dr.Dhanashri Dupade

Siddhi Gambhir SY
Aaditya Bhosle SY
Puja Kotawar SY
Ashwinikumar Sahani SY

Kishor Choudhary FY
Saara Shigwan FY
Kelash Oza FY
Vidisha Patekar FY

Mr.Aman Gupta

